Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 6;14:1228962. doi: 10.3389/fphar.2023.1228962

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Deng, Wang, Zhao, Tao, Zhang, Yang and Lei.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Anti-CD47-SIRPα axis antibody can block CD47-SIRPα signal transduction, restore the immune surveillance ability and immune clearance ability of macrophages to tumor cells. Firstly, negative regulatory signal transduction involving CD47 and SIRPα is inhibited, which improves the clearance efficiency of macrophages on tumor cells. Second, anti-CD47 antibodies induce an adaptive immune response to kill tumor cells. Thirdly, anti-CD47 antibodies bind to natural killer cells via the Fc portion, producing antibody-dependent cytotoxic effects (ADCC) and complement-dependent cytotoxic effects (CDC) to eliminate tumor cells. Finally, CD47-related antibodies promote the apoptosis process of tumor cells.